Previous 10 | Next 10 |
Savara (SVRA): Q3 GAAP EPS of -$0.18 misses by $0.01.Revenue of $256k.Cash, cash equivalents, and short-term investments of $94.3MPress Release For further details see: Savara EPS misses by $0.01
Company Outlines Near-Term Priorities Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today reported financial results for the third quarter ending September 30, 2020 and provided a business update. “After recently joining the management team, ...
Rob Neville Resigns as Chairman and Chief Executive Officer Matthew Pauls Appointed Chairman and Interim Chief Executive Officer Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Rob Neville has resigned as the Company’s Chief Executive Offic...
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Savara management will be presenting at the H.C. Wainwright Annual Investment Conference on Wednesday, September 16, 2020 at 3:00 PM EDT/12:00 PM PDT. Interested parties can access a live audio webcast on t...
Inhaled Molgramostim Improved Outcomes that Reflect Physiological, Radiological, Biochemical, and Clinical Manifestations of aPAP Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that results from the Phase 3 IMPALA study were published online in NEJM. The ...
Akebia reports data for its anemia drug candidate Akebia Therapeutics Inc. ( AKBA ) reported top-line data from the second of its two global Phase 3 cardiovascular outcomes programs, PRO2TECT. The two studies were designed to assess the efficacy and safety of vadadustat in comparison to ...
Citing a range of factors, including COVID-19 disruptions, that have compromised the expected outcome, Savara (NASDAQ: SVRA ) has discontinued the Phase 2a exploratory study, ENCORE , assessing lead drug Molgradex for the treatment of nontuberculous mycobacterial lung infection in cysti...
Study Stopped Enrolling in March 2020 Due to Limitations Caused by COVID-19 Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced the decision to discontinue ENCORE, a 48-week, open-label, non-controlled Phase 2a exploratory clinical study of Molgradex for the tre...
Savara Inc (SVRA) Q2 2020 Results Conference Call August 06, 2020 04:30 PM ET Company Participants Anne Erickson - Head Investor Relations Robert Neville - Chief Executive Officer Badrul Chowdhury - Chief Medical Officer Taneli Jouhikainen - President and Chief Business Office...
Savara (NASDAQ: SVRA ) : Q2 GAAP EPS of -$0.16 beats by $0.04 . More news on: Savara Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Remains On-Track to Report Top Line Data from the Pivotal Phase 3 IMPALA-2 Trial by End of 2Q 2024 48-week placebo-controlled trial is evaluating molgramostim nebulizer solution (molgramostim), a novel inhaled biologic, for the treatment of autoimmune Pulmonary Alveolar Proteinosis (aPAP)...
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Barclays 26th Annual Global Healthcare Conference on March 14, 2024 at 5:00am PT/8:00am ET. A live web...
Savara Inc. (NASDAQ: SVRA) has caught the attention of the investment community today with its bullish price action. The company's shares have moved 4.49% on the day to $5.35. Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candid...